12:00 AM
Nov 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Brodalumab: Phase III started

AstraZeneca disclosed in its 3Q12 earnings that enrollment began in the double-blind, international Phase III AMAGINE-1, -2 and -3 trials evaluating 140 and 210 mg subcutaneous brodalumab. AMAGINE-1 will enroll about 600 patients to compare brodalumab vs. placebo for 12 weeks. After 12 weeks, patients in the brodalumab arms will be re-randomized to receive placebo or continue...

Read the full 261 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >